RSS0343 / Jiangsu Hengrui Pharma - LARVOL DELTA

Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RSS0343 Tablets in Healthy Subjects After Single and Multiple Oral Administration and the Effect of Food on the Pharmacokinetics of RSS0343 (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial

Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis (clinicaltrials.gov) - P2 | N=252 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting | N=18 ➔ 252 | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Nov 2025 ➔ Nov 2027

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Asthma • Bronchiectasis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis (clinicaltrials.gov) - P2 | N=18 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P2 trial • Asthma • Bronchiectasis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases